Sign up to access all valuation multiples
Oscotec Inc is engaged in drug discovery for osteoporosis, arthritis, periodontal, dental health and cancer diseases.
1998
n/a
LTM Revenue $47.1M
Last FY EBITDA $1.4M
$931M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oscotec has a last 12-month revenue (LTM) of $47.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Oscotec achieved revenue of $24.3M and an EBITDA of $1.4M.
Oscotec expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oscotec valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $47.1M | XXX | $24.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $22.7M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 93% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $1.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 6% | XXX | XXX | XXX |
| EBIT | $18.8M | XXX | -$2.0M | XXX | XXX | XXX |
| EBIT Margin | 40% | XXX | -8% | XXX | XXX | XXX |
| Net Profit | $11.6M | XXX | $0.6M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Oscotec's stock price is KRW 36750 (or $26).
Oscotec has current market cap of KRW 1.41T (or $1.0B), and EV of KRW 1.30T (or $931M).
See Oscotec trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $931M | $1.0B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Oscotec has market cap of $1.0B and EV of $931M.
Oscotec's trades at 38.4x EV/Revenue multiple, and 684.2x EV/EBITDA.
Equity research analysts estimate Oscotec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oscotec has a P/E ratio of 86.2x.
See valuation multiples for Oscotec and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $931M | XXX | $931M | XXX | XXX | XXX |
| EV/Revenue | 19.8x | XXX | 38.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 684.2x | XXX | XXX | XXX |
| EV/EBIT | 49.6x | XXX | -477.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 86.2x | XXX | 1603.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -48.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOscotec's last 12 month revenue growth is 66%
Oscotec's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Oscotec's rule of 40 is -541% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oscotec's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oscotec and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 66% | XXX | 90% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -541% | XXX | 71% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 101% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oscotec acquired XXX companies to date.
Last acquisition by Oscotec was XXXXXXXX, XXXXX XXXXX XXXXXX . Oscotec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Oscotec founded? | Oscotec was founded in 1998. |
| Where is Oscotec headquartered? | Oscotec is headquartered in South Korea. |
| Who is the CEO of Oscotec? | Oscotec's CEO is Mr. Jeong-Geun Kim. |
| Is Oscotec publicy listed? | Yes, Oscotec is a public company listed on KRX. |
| What is the stock symbol of Oscotec? | Oscotec trades under 039200 ticker. |
| When did Oscotec go public? | Oscotec went public in 2007. |
| Who are competitors of Oscotec? | Similar companies to Oscotec include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Oscotec? | Oscotec's current market cap is $1.0B |
| What is the current revenue of Oscotec? | Oscotec's last 12 months revenue is $47.1M. |
| What is the current revenue growth of Oscotec? | Oscotec revenue growth (NTM/LTM) is 66%. |
| What is the current EV/Revenue multiple of Oscotec? | Current revenue multiple of Oscotec is 19.8x. |
| Is Oscotec profitable? | Yes, Oscotec is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
